Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Massanella, Marta ^a   Gianella, Sara ^a   Schrier, Rachel ^a   Dan, Jennifer M ^a,b   Pérez Santiago, Josué ^a   Oliveira, Michelli F ^a   Richman, Douglas D ^a,c   Little, Susan J ^a   Benson, Constance A ^a   Daar, Eric S ^d   Dube, Michael P ^e   Haubrich, Richard H ^a   Smith, Davey M ^a,c   Morris, Sheldon R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; METHAMPHETAMINE; VIRUS DNA;

ADULT; CASE CONTROL STUDY; CELL PROLIFERATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONOCYTE; T LYMPHOCYTE; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CELL PROLIFERATION; DNA, VIRAL; HIV ANTIGENS; HIV INFECTIONS; HUMANS; METHAMPHETAMINE; MIDDLE AGED; MONOCYTES; RECEPTORS, CCR5; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84940094631     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13179     Document Type: Article

References (48)

1. Durell, T. M., Kroutil, L. A., Crits-Christoph, P., Barchha, N. & Van Brunt, D. L. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy 3, 19 (2008).
2. Maxwell, J. C. & Rutkowski, B. A. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 27, 229-235 (2008).
3. Gonzales, R., Mooney, L. & Rawson, R. A. The methamphetamine problem in the United States. Annu Rev Public Health 31, 385-398 (2010).
4. Colfax, G. & Shoptaw, S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep 2, 194-199 (2005).
5. Harris, D. S. et al. The bioavailability of intranasal and smoked methamphetamine. Clin. Pharmacol. Ther. 74, 475-486 (2003).
6. Cho, A. K., Melega, W. P., Kuczenski, R. & Segal, D. S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39, 161-166 (2001).
7. Tallóczy, Z. et al. Methamphetamine Inhibits Antigen Processing, Presentation, and Phagocytosis. PLoS Pathog 4, e28 (2008).
8. Martinez, L. R., Mihu, M. R., Gácser, A., Santambrogio, L. & Nosanchuk, J. D. Methamphetamine enhances histoplasmosis by immunosuppression of the host. J Infect Dis 200, 131-141 (2009).
9. Potula, R. et al. Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. The Journal of Immunology 185, 2867-2876 (2010).
10. Colfax, G. N. et al. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 21, 239-241 (2007).
11. Fairbairn, N. et al. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Behav 36, 762-763 (2011).
12. Ellis, R. J. et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188, 1820-1826 (2003).
13. Carrico, A. W., Johnson, M. O., Colfax, G. N. & Moskowitz, J. T. Affective correlates of stimulant use and adherence to antiretroviral therapy among HIV-positive methamphetamine users. AIDS Behav 14, 769-777 (2010).
14. Kapadia, F. et al. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 100, 990-1002 (2005).
15. Shoptaw, S. & Reback, C. J. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction 102 Suppl 1, 130-135 (2007).
16. Patel, D. et al. Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain. MBio 4, (2013). doi: 10.1128/mBio.00400-13.
17. Stahlman, S., Javanbakht, M., Stirland, A., Guerry, S. & Gorbach, P. M. Methamphetamine Use Among Women Attending Sexually Transmitted Disease Clinics in Los Angeles County. Sexually Transmitted Diseases 40, 632-638 (2013).
18. Gonzales, R., Marinelli-Casey, P., Shoptaw, S., Ang, A. & Rawson, R. A. Hepatitis C virus infection among methamphetaminedependent individuals in outpatient treatment. Journal of Substance Abuse Treatment 31, 195-202 (2006).
19. Molitor, F., Truax, S. R., Ruiz, J. D. & Sun, R. K. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West. J. Med. 168, 93-97 (1998).
20. Mimiaga, M. J. et al. Experiences and sexual behaviors of HIV-infected MSM who acquired HIV in the context of crystal methamphetamine use. AIDS Educ Prev 20, 30-41 (2008).
21. Nair, M. P. N. et al. Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells. J Neuroimmune Pharmacol 4, 129-139 (2009).
22. Nair, M. P. N. & Saiyed, Z. M. Effect of methamphetamine on expression of HIV coreceptors and CC-chemokines by dendritic cells. Life Sci. 88, 987-994 (2011).
23. Potula, R. & Persidsky, Y. Adding fuel to the fire: methamphetamine enhances HIV infection. Am J Pathol 172, 1467-1470 (2008).
24. Toussi, S. S. et al. Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses 25, 1117-1121 (2009).
25. Okoye, A. et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 204, 2171-2185 (2007).
26. Klasse, P. J. The molecular basis of HIV entry. Cell. Microbiol. 14, 1183-1192 (2012).
27. Gianella, S. et al. Cytomegalovirus Replication in Semen Is Associated with Higher Levels of Proviral HIV DNA and CD4+ T Cell Activation during Antiretroviral Treatment. Journal of virology 88, 7818-7827 (2014).
28. Bofill, M. et al. Increased numbers of primed activated CD8+ CD38+ CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (London, England) 10, 827-834 (1996).
29. Giorgi, J. V. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179, 859-870 (1999).
30. Massanella, M. et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS (London, England) 24, 959-968 (2010).
31. Gianella, S. et al. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. Journal of virology 88, 7818-7827 (2014).
32. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Publishing Group 15, 893-900 (2009).
33. Madden, E. et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (London, England) 22, 707-715 (2008).
34. Cassol, E. et al. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 13, 203 (2013).
35. Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16, 460-465 (2010).
36. Hatano, H. et al. Increase in 2-Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. J Infect Dis 208, 1436-1442 (2013).
37. Rippeth, J. D. et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10, 1-14 (2004).
38. Giorgi, J. V. et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 29, 346-355 (2002).
39. Hunt, P. W. et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17, 1907-1915 (2003).
40. Hunt, P. W. et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (London, England) 25, 2123-2131 (2011).
41. Wensing, A. M. J., Van Maarseveen, N. M. & Nijhuis, M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res. 85, 59-74 (2010).
42. Yu, Q. et al. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int. Immunopharmacol. 2, 951-962 (2002).
43. In, S.-W., Son, E.-W., Rhee, D.-K. & Pyo, S. Methamphetamine Administration Produces Immunomodulation in Mice. Journal of Toxicology and Environmental Health, Part A 68, 2133-2145 (2005).
44. Gianella, S. et al. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis 57, 441-447 (2013).
45. Gianella, S. et al. Virologic Correlates of Anti-CMV IgG Levels in HIV-1-Infected Men. J Infect Dis (2013). doi: 10.1093/infdis/jit434.
46. Gianella, S. et al. Associations between Virologic and Immunologic Dynamics in Blood and in the Male Genital Tract. Journal of virology 86, 1307-1315 (2012).
47. Butler, D. M. et al. The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med 2, 18re1 (2010).
48. Strain, M. C. et al. Highly Precise Measurement of HIV DNA by Droplet Digital PCR. Plos One 8, e55943 (2013).